Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
2.07.2008
UK House of Commons publishes report on NICE
The Uk Parliament published an extenive report on the National Institute for Clinical Excellence (NICE) - past performance and its potential role going forward, especially in relation to future drug pricing in the UK. A must read for anyone involved in global health technology assessment, health economics, pricing and market access matters.
No comments:
Post a Comment